Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients

A 42-year-old man was referred to our dermatology outpatient clinic with a widespread rash. Dermatological examination showed widespread, near total-body erythema with desquamation, along with scaly erythematous plaques on the extremities. Additionally, he had severe palmoplantar hyperkeratosis and fissuring, along with mild erythematous silvery-white scaly patches on the scalp. Pitting and onycholysis were noted on his all fingernails. Detailed history revealed that the patient has suffered from plaque psoriasis and psoriatic arthritis for 20 years and undergone numerous therapies including acitretin, methotrexate, and adalimumab without significant improvement. There-

supporting

confidence: 61%

Erythroderma related with the first dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine in a patient with psoriasis

Durmusl

Akdoğan

Karadağ

et al. 2022

“…[16][17][18] High weight does not seem to compromise the response to brodalumab, 19 the role of the weight in the response to ixekizumab shows contradictory results in the current literature. 18,20 In our study obesity proved to be a negative predictor of response to risankizumab in some of the outcomes analyzed: in the achievement of PASI 100 at week 28, reached by 22% of obese patients versus 58% of non-obese patients (p = 0.007), and in the mean PASI at 28 weeks 1.7 vs. 0.9 (p = 0.006). Other significant differences were seen in the attainment of PASI 100 at week 40 and PASI <3 at week 40.…”

Section: Discussionmentioning

confidence: 94%

“…A high BMI is a well-known negative predictor of psoriasis response to some biologic treatment as anti-TNFalpha, ustekinumab and secukinumab. [16][17][18] High weight does not seem to compromise the response to brodalumab, 19 the role of the weight in the response to ixekizumab shows contradictory results in the current literature. 18,20 In our study obesity proved to be a negative predictor of response to risankizumab in some of the outcomes analyzed: in the achievement of PASI 100 at week 28, reached by 22% of obese patients versus 58% of non-obese patients (p = 0.007), and in the mean PASI at 28 weeks 1.7 vs. 0.9 (p = 0.006).…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Mastorino

Susca

Megna

et al. 2022

Self Cite

Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response. We retrospectively analyzed 166 patients from two centers in Italy who undergone Risankizumab for psoriasis. The proportion of patients achieving a 100%, 90%, 75% of improvement in Psoriasis Area Severity Index (PASI) and PASI <3 were collected at weeks 16, 28, 40, and 52. Study population was analyzed in subgroups to investigate possible predictors of response to Risankizumab since week 40. At the time of analysis 165, 103, 30, and 11 patients had completed 16, 28, 40, and 52 weeks of treatment, respectively. The mean PASI score decreased from 12.5 ± 5.1 at baseline to 1.9 ± 2.4 at week 16. Similar reductions were observed when considering PASI <3, PASI 75, PASI 90, and PASI 100. Previous biologics failure, different smoking habits, obesity, and joint involvement resulted in a lower response to risankizumab. In particular, significant differences in mean PASI at any time‐points was observed between psoriatic arthritis (PSA) and non‐PSA patients: 2.7 versus 1.7 (p = 0.036), 1.9 versus 0.4 (p = 0.006), and 4.1 versus 0.5 (p = 0.016) at 16, 28, and 40 weeks, respectively. No difference in response to risankizumab occurred in the case of involvement of difficult‐to‐treat areas. In this population, Risankizumab was effective and safe. Smoking habits, joint involvement, obese status, and previous biologic experience may negatively affect treatment response, while difficult body sites involvement have minor impact.

“…31,52 Furthermore, real life studies compared ixekizumab with secukinumab are both highly effective in short-and long-term treatment of psoriasis, even though few differences exist concerning speed of action and long-term effectiveness, with a faster response in term of achieving PASI75 and PASI90 for ixekizumab. 54,55 Brodalumab efficacy and safety profiles were evaluated in three randomized double blinded controlled trials (AMAGINE-1, AMAGINE-2 and AMAGINE-3). These trials showed the superiority of brodalumab in achieving PASI75 respect to placebo in AMAGINE-1 (PASI75 achieved in 83.3%, 2.7% respectively), AMAGINE-2 (PASI75 86% and 8% respectively) and AMAGINE-3 trials (PASI75 85% and 6%, respectively).…”

Section: Discussionmentioning

confidence: 99%

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting

Megna

Potestio

Camela

et al. 2022

Eleven biologic drugs are currently approved for psoriasis management. Real-life studies are needed to guide clinicians in choosing a tailored-tail therapy. The aim of our retrospective study is to indirectly compare the efficacy and safety of ixekizumab and brodalumab in psoriasis patients. A single-centre real-life retrospective study was performed enrolling moderate-to-severe psoriatic patients under biologic treatment with ixekizumab or brodalumab. For each patient, clinical and demographic data were collected and the effectiveness and safety of brodalumab and ixekizumab treatment were evaluated at weeks 4, 12, and 24. Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) were used for psoriasis severity. A total of 139 patients were included in the study: 98(70.5%) and 41(29.5%) patients received ixekizumab and brodalumab, respectively.Mean PASI and BSA significantly reduced at each follow up for both ixekizumab and brodalumab groups. Even if ixekizumab reached higher rates of PASI90 and PASI100 than brodalumab (PASI90: 43.8% vs. 39.0% PASI100: 20.4% vs. 17.1% at week4 and PASI90: 83.6% vs. 75.6% PASI100: 71.5% vs. 60.9% at week24), these results were not statistically significant. Adverse events, mainly mild, were registered in 25.5% of ixekizumab and 26.8% of brodalumab group, respectively. Discontinuation rate was higher for brodalumab (17.1% vs. 9.1%), without statistical significance. Our study showed comparable efficacy and safety for ixekizumab and brodalumab.